Pancreatic Steatosis and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Systematic Review of the Current Evidence

Background: Pancreatic steatosis (PS) has emerged as a potential risk factor for pancreatic ductal adenocarcinoma (PDAC). While increasing evidence supports its role in pancreatic carcinogenesis, its prognostic significance after PDAC diagnosis remains unclear. We performed a systematic review to evaluate the association between PS and survival outcomes in patients with pancreatic cancer. Methods: A systematic search of PubMed and Scopus was conducted in May 2026 according to PRISMA guidelines. Observational studies assessing pancreatic steatosis by imaging or histology and reporting survival outcomes in PDAC patients were included. Risk of bias was evaluated using the Quality in Prognosis Studies (QUIPS) tool. Results: Five studies met inclusion criteria, comprising three imaging-based and two histology-based papers. Three studies reported findings suggestive of an adverse prognostic role of PS, whereas two found no significant association with survival. The strongest evidence originated from a study using quantitative histological assessment of pancreatic fat, which demonstrated that greater pancreatic fat accumulation was independently associated with poorer overall survival and recurrence-free survival following surgical resection. In contrast, imaging-based studies yielded inconsistent results. Histology-based studies consistently supported a negative prognostic impact, whereas CT-derived attenuation measures showed substantial variability. Risk of bias was moderate to high in most studies, largely due to retrospective designs, small sample sizes, heterogeneous definitions of pancreatic steatosis, and incomplete adjustment for metabolic confounders. Conclusions: Current evidence regarding the prognostic value of pancreatic steatosis in PDAC is limited and conflicting. While histology-based studies suggest an adverse impact on survival, imaging-based data remain inconsistent.